Biotest records sales and operating profit rise in 2013

Biotest increased its sales by 13.8 percent last year.

The company released its full-year report this week and it shows the rise was enough to push total sales beyond the 500 million euro (413 million pound) mark for the first time, up from 440 million euros in the last financial year.

Biotest's launch of Bivigam in the US helped the company achieve this strong growth, allowing sales in the therapy segment to increase 16.7 percent from 330.9 million euros to EUR 386.2 million euros.

Sales also continued to grow in Germany in 2013, up 4.5 percent compared to the previous year.

As a result of these positive sales figures, Biotest was able to increase operating profit by 20.4 percent to 53.8 million euros in 2013, a rise from 44.7 million euro in 2012.

The Board of Management expects Biotest's sales and operating profit in the financial year 2014 to grow in the range of ten per cent.